Smital Shah

Ms. Shah has a 17-year track record of leadership and management in the biopharmaceutical industry, as well as in investment banking, with particular experience in financial strategy, capital markets, and business development. She is a chief business and financial officer at rare disease company ProQR, which she joined as a chief financial officer in 2014. Previously, Ms. Shah managed the multi-billion-dollar debt, cash, and investment portfolios of Gilead Sciences. Prior to Gilead, she was an investment banker at Leerink Partners and JP Morgan where she helped raise over $1 billion in equity capital and over $7 billion in debt capital for emerging and established biotech companies and advised on M&A. Previously, Ms. Shah held various R&D roles at Johnson & Johnson. She earned both bachelor’s and master’s degrees in chemical engineering and an MBA from the University of California at Berkeley.